Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers

Nuclear Medicine Communications

Volumn 34, Issue 9, 2013, Pages 915-925

  Shanehsazzadeh, Saeed ^a,c   Oghabian, Mohammad A ^a,c   Lahooti, Afsaneh ^a   Abdollahi, Mohammad ^d   Abolghasem Haeri, Seyed ^c   Amanlou, Massoud ^b   Daha, Fariba J ^c   Allen, Barry J ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ATOMIC ENERGY ORGANIZATION OF IRAN   (Iran)

^d BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

67Ga; biodistribution; liver; nanoparticles; ultrasmall superparamagnetic iron oxide

Indexed keywords

GALLIUM 67; PENTETATE GALLIUM GA 67 ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; PENTETIC ACID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; CONTROLLED STUDY; DOSIMETRY; DRUG STABILITY; FEMALE; ISOTOPE LABELING; LIVER CANCER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; PURIFICATION; RADIATION DOSE; SPLEEN CANCER; TREATMENT OUTCOME;

ANIMALS; BACKGROUND RADIATION; FEMALE; FERRIC COMPOUNDS; GADOLINIUM DTPA; GALLIUM RADIOISOTOPES; HUMANS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MAGNETS; MALE; MICE; MICE, INBRED BALB C; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; SPLENIC NEOPLASMS;

EID: 84881536388     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328362d2fb     Document Type: Article

References (34)

1. Oghabian MA, Farahbakhsh NM. Potential use of nanoparticle based contrast agents in MRI: a molecular imaging perspective. J Biomed Nanotechnol 2010; 6:203-213.
2. Shanehsazzadeh S, Oghabian MA, Daha FJ, Amanlou M, Allen BJ. Biodistribution of ultrasmall superparamagnetic iron oxide nanoparticles in BALB mice. J Radioanal Nucl Chem 2013; 295:1517-1523.
3. 3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent. Int J Nanomedicine 2011; 6:747-763.
4. 99mTc-radiopharmaceuticals based on gold nanoparticles. Nucl Med Commun 2011; 32:1095-1104.
5. Oghabian MA, Gharehaghaji N, Masoudi A, Shanehsazzadeh S, Ahmadi R, Majidi R, Hosseini HRM. Effect of coating materials on lymph nodes detection using magnetite nanoparticles. Adv Sci Eng Med 2013; 5:37-45.
6. Shanehsazzadeh S, Oghabian M, Allen B, Amanlou M, Masoudi A, Daha F. Evaluating the effect of ultrasmall superparamagnetic iron oxide nanoparticles for a long-term magnetic cell labeling. J Med Phys 2013; 38:34-40.
7. Shanehsazzadeh S, Oghabian MA, Allen BJ, Amanlou M, Johari Daha F. Evaluating the effect of USPIO nanoparticles for 21 days post magnetic cell labeling. In: Long M, editor. World congress on medical physics and biomedical engineering May 26-31, 2012, Beijing, China. Berlin Heidelberg: Springer; 2013. pp. 2204-2207.
8. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002; 9:S304-S306.
9. Shahbazi-Gahrouei D, Abdolahi M, Zarkesh-Esfahani SH, Laurent S, Sermeus C, Gruettner C. Functionalized magnetic nanoparticles for the detection and quantitative analysis of cell surface antigen. Biomed Res Int 2013; 2013:349408.
10. Bakht MK, Sadeghi M, Ahmadi SJ, Sadjadi SS, Tenreiro C. Preparation of radioactive praseodymium oxide as a multifunctional agent in nuclear medicine: expanding the horizons of cancer therapy using nanosized neodymium oxide. Nucl Med Commun 2013; 34:5-12.
11. Gharehaghaji N, Oghabian MA, Sarkar S, Darki F, Beitollahi A. How size evaluation of lymph node is protocol dependent in MRI when using ultrasmall superparamagnetic iron oxide nanoparticles. J Magn Magn Mater 2009; 321:1563-1565.
12. Barcena C, Sra AK, Gao J. Applications of magnetic nanoparticles in biomedicine. In: Liu P, Sellmyer D, Fullerton E, Gutfleisch O, editors. Nanoscale magnetic materials and applications. New York: Springer Science & Business Media Inc.; 2009. pp. 591-626.
13. Oghabian MA, Jeddi-Tehrani M, Zolfaghari A, Shamsipour F, Khoei S, Amanpour S. Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. J Nanosci Nanotechnol 2011; 11:5340-5344.
14. Feng JH, Liu HL, Bhakoo KK, Lu LH, Chen Z. A metabonomic analysis of organ specific response to USPIO administration. Biomaterials 2011; 32:6558-6569.
15. Oghabian MA, Gharehaghaji N, Amirmohseni S, Khoei S, Guiti M. Detection sensitivity of lymph nodes of various sizes using USPIO nanoparticles in magnetic resonance imaging. Nanomedicine 2010; 6:496-499.
16. 111In-DTPA-buserelin in human on the basis of biodistribution rat data. Radiat Prot Dosimetry 2012; 154:1-8.
17. Khorrami Moghaddam A, Reza Jalilian A, Hayati V, Shanehsazzadeh S. Determination of human absorbed dose of 201Tl(III)-DTPA-HIgG based on biodistribution data in rats. Radiat Prot Dosimerty 2010; 141:269-274.
18. 111In]-DTPA-buserelin for GnRH receptor studies. Radiochimica Acta 2010; 98:113-119.
19. Jalilian AR, Shanehsazzadeh S, Akhlaghi M, Garoosi J, Rajabifar S, Tavakoli AB. Preparation and evaluation [Ga-67]-DTPA-beta-1-24-corticotrophin in normal rats. Radiochimica Acta 2008; 96:435-439.
20. 67Ga-cDTPA-gonadorelin based on biodistribution rat data. Nucl Med Commun 2011; 32:37-43.
21. 67Ga]-DTPA- gonadorelin in normal rats. J Labelled Compd Rad 2009; 52:S326-S326.
22. 67GA-DTPA-ACTH based on distribution data in rats. Radiat Prot Dosimetry 2009; 134:79-86.
23. Snyder WS, Ford MR, Warner GG. Committee SoNMMIRD. Estimates of specific absorbed fractions for photon sources: uniformly distributed in various organs of a heterogeneous phantom. New York: Society of Nuclear Medicine; 1978.
24. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm 2005; 20:126-140.
25. Snyder W, Ford M, Warner G, Watson S. S" absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: MIRD, Society of Nuclear Medicine; 1975.
26. Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Paper presented at Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1999.
27. ICRP. International Commission on Radiological Protection, ICRP Publication 103. Ann ICRP 2007; 37: 1-332.
28. Tabatabaei SN, Lapointe J, Martel S. Hydrogel encapsulated magnetic nanoparticles as hyperthermic actuators for microrobots designed to operate in the vascular network. Intelligent Robots and Systems, 2009 IROS 2009 IEEE/RSJ International Conference; 10-15 October 2009.
29. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55:329-347.
30. 99mTc-pertechnetate. J Radioanal Nucl Chem 2010; 284:405-413.
31. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. JMRI-J Magn Reson Imaging 1997; 7:1140-1145.
32. Weissleder R, Stark D, Engelstad B, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 1989; 152:167-173.
33. Qin J, Laurent S, Jo YS, Roch A, Mikhaylova M, Bhujwalla ZM, et al. A high-performance magnetic resonance imaging T-2 contrast agent. Adv Mater 2007; 19:1874-1878.
34. Trubetskoy VS, Torchilin VP. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. J Liposome Res 1994; 4:961-980.